Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement

Arthritis Research and Therapy

Volumn 14, Issue 4, 2012, Pages

  Valentini, Gabriele ^a   Vettori, Serena ^a   Cuomo, Giovanna ^a   Iudici, Michele ^a   D'Abrosca, Virginia ^a   Capocotta, Domenico ^a   Del Genio, Gianmattia ^b   Santoriello, Carlo ^c   Cozzolino, Domenico ^d  

^a Unit of Rheumatology   (Italy)

^b Unit of General Surgery   (Italy)

^c XCom Wide Communication   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA; PROCOLLAGEN; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; B SCAN; CLINICAL EVALUATION; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE COURSE; ESOPHAGUS FUNCTION DISORDER; ESOPHAGUS MANOMETRY; FEMALE; FIBROBLAST; FINGER ULCER; HEART MUSCLE FIBROSIS; HUMAN; KIDNEY FAILURE; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; SCLERODERMA; SKIN CALCIFICATION; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION; TELANGIECTASIA; UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE; ANGIOSCOPY; BLOOD; EARLY DIAGNOSIS; FOLLOW UP; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; PREDICTIVE VALUE; PROCEDURES; RADIOGRAPHY; RAYNAUD PHENOMENON; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MICROSCOPIC ANGIOSCOPY; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; PREDICTIVE VALUE OF TESTS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; YOUNG ADULT;

EID: 84865048745     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4019     Document Type: Article

References (28)

1. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007, 66:754-763. 10.1136/ard.2006.062901, 1954657, 17234652.
2. Spencer-Green G. Outcomes in primary Raynaud phenomenon: a metaanalysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 1998, 158:595-600. 10.1001/archinte.158.6.595, 9521223.
3. Fine LG, Denton CP, Black CM, Korn JH, de Cambrugge B. Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy (Report of a Meeting of Physicians and Scientists, Royal Free Hospital, School of Medicine, London). Lancet 1996, 347:1453-1458. 10.1016/S0140-6736(96)91687-6, 8676631.
4. LeRoy EC, Medsger TA. Criteria for the classification of early Systemic Sclerosis. J Rheumatol 2001, 28:1573-1576.
5. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510, 7378088, Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
6. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, Goulet JR, Rich E, Grodzicky T, Raymond Y, Senécal JL. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis. A twenty-year prospective study of 586 patients with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008, 58:3902-3912. 10.1002/art.24038, 19035499.
7. LeRoy EC, Medsger TA. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992, 10:485-489.
8. Sebastiani M, Manfredi A, Vukatana G, Moscatelli S, Riato L, Bocci M, Iudici M, Principato A, Mazzuca S, Del Medico P, De Angelis R, D'Amico R, Vicini R, Colaci M, Ferri C. Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study. Ann Rheum Dis 2012, 71:67-70. 10.1136/annrheumdis-2011-200022, 21917823.
9. Maricq HR. Widefield capillary microscopy: technique and rating scale for abnormalities seen in scleroderma and related disorders. Arthritis Rheum 1981, 24:1159-1165. 10.1002/art.1780240907, 7306237.
10. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, Raymond Y, Senécal JL. Predicting mortality in systemic sclerosis. Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002, 81:154-167.
11. Valentini G, Cuomo G, Abignano G, Petrillo A, Vettori S, Capasso A, Cozzolino D, Del Genio G, Santoriello C. Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) 2011, 50:317-323.
12. Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 1999, 17:615-620.
13. Doria A, Mosca M, Gambari PF, Bombardieri S. Defining unclassifiable connective tissue diseases: incomplete, undifferentiated or both?. J Rheumatol 2005, 32:3-5.
14. Maione S, Cuomo G, Giunta A, Tanturri de Horatio L, La Montagna G, Manguso F, Alagia I, Valentini G. Echocardiographic alterations in systemic sclerosis. A longitudinal study. Semin Arthritis Rheum 2005, 34:721-727. 10.1016/j.semarthrit.2004.11.001, 15846587.
15. Paone C, Chiarolanza I, Cuomo G, Ruocco L, Vettori S, Menegozzo M, La Montagna G, Valentini G. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 2007, 25:613-616.
16. Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985, 28:759-767. 10.1002/art.1780280706, 4015723.
17. Nakajma K, Taki J, Kawano M, Higuchi T, Sato S, Nishijima C, Takehara K, Tonami N. Diastolic dysfunction in patients with systemic sclerosis detected by gated myocardial perfusion SPECT: an early sign of cardiac involvement. J Nucl Med 2001, 42:183-188.
18. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994, 37:1265-1282. 10.1002/art.1780370902, 7945489.
19. Harper FE, Maricq HR, Turner RE, Lidman RW, LeRoy EC. A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. Am J Med 1982, 72:883-888. 10.1016/0002-9343(82)90846-4, 7091158.
20. Kallenberg CGM, Pastoor GW, Wouda AA, The TH. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis 1982, 41:382-387. 10.1136/ard.41.4.382, 1000955, 7051989.
21. Gerbracht DD, Steen VD, Ziegler GL, Medsger TA, Rodnan GP. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. Arthritis Rheum 1985, 28:87-92. 10.1002/art.1780280114, 3871330.
22. Fitzgerald O, Hess EV, O'Connor GT, Spencer-Green G. Prospective study of the evolution of Raynaud's phenomenon. Am J Med 1988, 84:718-726. 10.1016/0002-9343(88)90109-X, 3261127.
23. Kallenberg CG, Wouda AA, Hoet MH, Van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988, 47:634-641. 10.1136/ard.47.8.634, 1006713, 3261966.
24. Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer-Green G. The evolution of Raynaud's phenomenon: a longterm prospective study. J Rheumatol 1995, 22:2226-2232.
25. Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter H-P, Kundi M. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease. Results of ten years of prospective surveillance. Arthritis Rheum 2006, 54:1974-1981. 10.1002/art.21912, 16732585.
26. Ingegnoli F, Boracchi P, Gualtierotti R, Lubatti C, Meani L, Zahalkova L, Zeni S, Fantini F. A prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorders. Arthritis Rheum 2008, 58:2174-2182. 10.1002/art.23555, 18576359.
27. Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986, 13:911-916.
28. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, Miniati I, Tarner IH, Randone SB, Cutolo M, Allanore Y, Distler O, Valentini G, Czirjak L, Müller-Ladner U, Furst DE, Tyndall A, Matucci-Cerinic M, . EUSTAR Group Ann Rheum Dis 2011, 70:476-481. 10.1136/ard.2010.136929, 21081523, EUSTAR Group.